Terns Pharmaceuticals Stock Earnings Per Share
| TERN Stock | USD 6.34 0.46 7.82% |
Terns Pharmaceuticals fundamentals help investors to digest information that contributes to Terns Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Terns Stock. The fundamental analysis module provides a way to measure Terns Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Terns Pharmaceuticals stock.
Terns | Earnings Per Share |
Terns Pharmaceuticals Company Earnings Per Share Analysis
Terns Pharmaceuticals' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Terns Pharmaceuticals Earnings Per Share | (1.18) X |
Most of Terns Pharmaceuticals' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Terns Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Terns Earnings Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Terns Pharmaceuticals is extremely important. It helps to project a fair market value of Terns Stock properly, considering its historical fundamentals such as Earnings Per Share. Since Terns Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Terns Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Terns Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
Terns Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
According to the company disclosure, Terns Pharmaceuticals has an Earnings Per Share of -1.18 times. This is 114.1% lower than that of the Pharmaceuticals sector and 75.37% lower than that of the Health Care industry. The earnings per share for all United States stocks is 137.82% higher than that of the company.
Terns Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Terns Pharmaceuticals' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Terns Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Terns Pharmaceuticals by comparing valuation metrics of similar companies.Terns Pharmaceuticals is currently under evaluation in earnings per share category among its peers.
Terns Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Terns Pharmaceuticals from analyzing Terns Pharmaceuticals' financial statements. These drivers represent accounts that assess Terns Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Terns Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 461.5M | 462.1M | 178.7M | 366.8M | 421.8M | 420.2M | |
| Enterprise Value | 449.2M | 400.1M | 131.0M | 224.8M | 258.5M | 343.9M |
Terns Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Terns Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Terns Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Terns Fundamentals
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 127.97 M | ||||
| Shares Outstanding | 84.94 M | ||||
| Shares Owned By Insiders | 0.13 % | ||||
| Shares Owned By Institutions | 97.72 % | ||||
| Number Of Shares Shorted | 4.54 M | ||||
| Price To Book | 1.37 X | ||||
| Price To Sales | 302.64 X | ||||
| Gross Profit | 1000 K | ||||
| EBITDA | (102.56 M) | ||||
| Net Income | (90.21 M) | ||||
| Cash And Equivalents | 139.81 M | ||||
| Cash Per Share | 5.51 X | ||||
| Total Debt | 603 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 23.59 X | ||||
| Book Value Per Share | 4.29 X | ||||
| Cash Flow From Operations | (67.39 M) | ||||
| Short Ratio | 3.16 X | ||||
| Earnings Per Share | (1.18) X | ||||
| Target Price | 18.19 | ||||
| Number Of Employees | 66 | ||||
| Beta | -0.33 | ||||
| Market Capitalization | 499.44 M | ||||
| Total Asset | 268.52 M | ||||
| Retained Earnings | (332.63 M) | ||||
| Working Capital | 255.49 M | ||||
| Net Asset | 268.52 M |
About Terns Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Terns Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Terns Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Terns Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Terns Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Terns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Terns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Terns Stock
| 0.68 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.65 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.64 | LLY | Eli Lilly Sell-off Trend | PairCorr |
Moving against Terns Stock
| 0.75 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.66 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.59 | ESLAW | Estrella Immunopharma | PairCorr |
| 0.59 | PMVP | Pmv Pharmaceuticals | PairCorr |
| 0.53 | GILD | Gilead Sciences | PairCorr |
The ability to find closely correlated positions to Terns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Terns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Terns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Terns Pharmaceuticals to buy it.
The correlation of Terns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Terns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Terns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Terns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Terns Pharmaceuticals Piotroski F Score and Terns Pharmaceuticals Altman Z Score analysis. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.18) | Revenue Per Share 0.035 | Return On Assets (0.19) | Return On Equity (0.28) |
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.